LJI308

Key Product Details

Product Description

LJI308 is a potent pan-ribosomal S6 protein kinase (RSK) inhibitor (IC₅₀ values are 4 to 13 nM). Displays selectivity for RSK isoforms over other kinases. Inhibits RSK-dependent Y-box binding protein 1 (YB-1) phosphorylation in vitro. Suppresses growth of triple negative breast cancer cell lines.

Product Specifications for LJI308

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LJI308

The following data is based on the product molecular weight 368.38.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.43 mL	27.15 mL	54.29 mL
2.5 mM	1.09 mL	5.43 mL	10.86 mL
5 mM	0.54 mL	2.71 mL	5.43 mL
25 mM	0.11 mL	0.54 mL	1.09 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Aronchik Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. Mol.Cancer Res. 2014 PMID: 24554780
• Davies Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells. Oncotarget. 2015 PMID: 26011941
• Jain Discovery of potent and selective RSK inhibitors as biological probes. J.Med.Chem. 2015 PMID: 26270416

Product Documents for LJI308